Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA

Amova Asset Management Americas Inc. reduced its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 11.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,354,856 shares of the company’s stock after selling 316,409 shares during the quarter. Amova Asset Management Americas Inc. owned approximately 2.03% of Intellia Therapeutics worth $40,621,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of NTLA. CWM LLC boosted its stake in Intellia Therapeutics by 4.7% in the third quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after acquiring an additional 856 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Intellia Therapeutics by 39.7% in the 3rd quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after purchasing an additional 927 shares in the last quarter. Cyndeo Wealth Partners LLC increased its position in Intellia Therapeutics by 9.3% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after buying an additional 995 shares in the last quarter. Interchange Capital Partners LLC increased its position in Intellia Therapeutics by 9.7% during the 3rd quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after buying an additional 1,030 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of Intellia Therapeutics by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after purchasing an additional 1,126 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $13.82 on Thursday. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.25. The stock has a market capitalization of $1.63 billion, a PE ratio of -3.61 and a beta of 2.10. The business has a 50 day simple moving average of $12.17 and a 200-day simple moving average of $13.10.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.16. The company had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm’s revenue was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.27) EPS. On average, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NTLA. Robert W. Baird set a $7.00 price target on shares of Intellia Therapeutics in a report on Tuesday, January 27th. Oppenheimer set a $27.00 target price on Intellia Therapeutics in a research report on Friday, November 7th. Canaccord Genuity Group reduced their price target on shares of Intellia Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday. KeyCorp set a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, January 28th. Finally, HC Wainwright increased their price objective on shares of Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday. Eleven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.59.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the sale, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. The trade was a 9.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,051 shares of company stock worth $488,600 in the last 90 days. Insiders own 3.10% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.